Highlights of weekly biotech stock moves

Biotie Therapies Corp. (HSE:BTH1V) gained €0.18 (36%) to €0.68 on Monday after partner H. Lundbeck A/S (CSE:LUN) said it plans to submit an MAA next half for nalmefene to treat alcohol addiction. Biotie was up €0.07 (14%) to €0.57 last week.

Celgene Corp. (NASDAQ:CELG) gained $0.02 to $59.16 last week after submitting an MAA to EMA for Revlimid lenalidomide as maintenance treatment for newly diagnosed multiple myeloma (MM) in patients who have not progressed following initial treatment with melphalan, prednisone and Revlimid, or following autologous stem cell transplantation...